What Factors Contributed to the 11.5% Growth in India's Pharma Market in June?
Click to start listening
Synopsis
Discover how India's pharmaceutical market achieved an impressive 11.5% growth in June, driven by acute therapies. This report uncovers the key factors behind this surge and the performance of domestic companies versus MNCs.
Key Takeaways
- 11.5% YoY growth in Indian pharma market.
- Strong performance in acute therapies.
- Domestic companies hold 84% market share.
- Cardiac therapies grew by 11.8%.
- Anti-infectives showed significant recovery.
New Delhi, July 16 (NationPress) The Indian pharmaceutical market (IPM) experienced a remarkable growth rate of 11.5% year-on-year (YoY) in June, attributed to a surge in acute therapies, as detailed in a report released on Wednesday.
By contrast, June of the previous year saw the IPM grow by 7%. The report from Motilal Oswal Financial Services highlighted that the pharma market recorded a growth of 6.9% in May 2025.
The report emphasized that the recent growth was fueled by substantial performance in sectors like respiratory, cardiac, central nervous system (CNS), and pain therapies, all of which surpassed the overall IPM growth in June.
The growth in the acute therapy segment reached 11% in June (compared to 7% in June 2024 and 5% in May 2025) driven by seasonal factors. Notably, anti-infectives displayed significant recovery in YoY growth in June compared to prior months.
The factors contributing to the IPM growth over the past year included price increases (4.2%), new product launches (2.3%), and volume growth (1.5%), as per the report.
Moreover, the industry reported an 8% YoY growth on a moving annual turnover (MAT) basis.
Chronic therapies showed a 10% YoY growth, whereas acute therapies reflected a 6.8% YoY growth. Among them, cardiac therapies recorded the highest growth at 11.8% YoY, followed closely by CNS at 9.1%, and derma at 8.6%.
The anti-infectives and respiratory segments underperformed the IPM by 290 basis points and 250 basis points on a YoY basis.
The share of the acute segment in the overall IPM stood at 60.8% for MAT June, with a YoY growth of 6.8%, according to the report.
Additionally, the report highlighted that domestic companies outperformed multi-national pharmaceutical companies (MNCs) in June.
As of June, Indian pharmaceutical companies held a dominant 84% share in the IPM, while MNCs accounted for the remaining share. Indian companies achieved a growth rate of 11.6% in June 2025, while MNCs recorded 11.2% YoY growth, as stated in the report.
Point of View
It is essential to recognize the resilience and adaptability of the Indian pharmaceutical sector. The 11.5% growth amidst challenges reflects the commitment of domestic companies to innovate and cater to public health needs. The dominance of Indian firms over MNCs is noteworthy, signaling a robust and competitive market landscape.
NationPress
16/07/2025
Frequently Asked Questions
What is the growth rate of the Indian pharma market in June 2025?
The Indian pharma market grew by 11.5% year-on-year in June 2025.
Which segments contributed to the growth in the pharma market?
The growth was driven by segments such as respiratory, cardiac, CNS, and pain therapies.
How did domestic companies perform compared to MNCs?
Domestic pharmaceutical companies outperformed MNCs, achieving a growth rate of 11.6% compared to 11.2% for MNCs.
